{
    "pmcid": "8651292",
    "qa_pairs": {
        "How do nanobodies neutralize the SARS-CoV-2 virus as mentioned in the summary?": [
            "By blocking ACE2 binding and preventing conformational changes necessary for membrane fusion",
            "By degrading the viral RNA genome",
            "By enhancing the host's immune response to the virus",
            "By disrupting the viral lipid membrane"
        ],
        "What advantage do nanobodies have over conventional antibodies according to the summary?": [
            "They can bind to unique epitopes inaccessible to conventional antibodies",
            "They have a larger size allowing for more robust binding",
            "They are derived from human antibodies, reducing immunogenicity",
            "They require less time to develop than conventional antibodies"
        ],
        "What is the primary function of the SARS-CoV-2 spike protein as described in the summary?": [
            "Facilitating viral entry into host cells by binding to the ACE2 receptor",
            "Providing structural integrity to the virus",
            "Serving as a primary target for antiviral drugs",
            "Acting as a decoy to evade the host immune system"
        ],
        "What potential therapeutic application of nanobodies is highlighted in the summary?": [
            "Direct delivery to the lungs via nebulization for rapid and localized treatment",
            "Oral administration for systemic distribution",
            "Intravenous injection for immediate bloodstream circulation",
            "Topical application for skin-related viral infections"
        ],
        "What strategy is used to ensure nanobodies retain effectiveness against SARS-CoV-2 variants?": [
            "Targeting conserved epitopes and using combinations that reduce the likelihood of escape mutations",
            "Increasing the dosage of nanobodies administered",
            "Focusing on the development of monoclonal nanobodies",
            "Altering the nanobody structure to mimic viral mutations"
        ]
    }
}